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Abstract
The purpose of this study was to evaluate the role of XPD genotypes as genetic indicator of susceptibility to ovarian cancer. We
have used a case–control study. We analysed DNA samples from 141 ovarian cancer patients and 202 control subjects, for three
XPD polymorphisms using PCR-RFLP. We observed that Asn312Asn XPD genotype carriers have increased susceptibility of
ovarian cancer (ORZ2.46 95% CI 1.20–5.06; PZ0.015). Furthermore, we found that carriers of Gln751Gln XPD genotype have
an increased susceptibility of ovarian cancer (ORZ3.40 95% CI 1.61–7.15; PZ0.001). Asn312Asn and Gln751Gln are particularly
associated with an early-stage of disease. Our results suggest an important role for Asn312Asn and Gln751Gln XPD poly-
morphisms in the susceptibility to ovarian cancer.
q 2006 Published by Elsevier Ireland Ltd.
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Ovarian cancer has the highest mortality rate of all
gynaecologic cancers because it is seldom diagnosed at
an early stage, when the likelihood of remission is
greatest [1]. In this way, it is very important to define
the factors concerned in the carcinogenesis of ovarian
cancer, trying to help to an early detection of this
disease.
Nucleotide excision repair (NER) is the most
important and versatile pathway by which mammalian
cells removes DNA lesions caused by physical and0304-3835/$ - see front matter q 2006 Published by Elsevier Ireland Ltd.
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unrelated lesions such as ultra violet (UV) induced
photoproducts, bulky chemical DNA adducts, and
particularly distorting interstrand cross links, induced
by chemotherapeutic agents, are efficiently removed by
the NER pathway [2,3]. A considerable inter-individual
variation in DNA repair capacity has been observed in
the general population, and it has been reported that
individuals with variable NER capacity are at increased
risk of developing cancer [4,5]. Therefore, polymorph-
isms in DNA repair genes have the potential to be
cancer risk factors in the population.
In NER pathway, the products of more than a dozen
genes are involved in the process of restoring the
normal structure [2]. Xeroderma pigmentosum Group D
(XPD), also known as ERCC2, is an essential memberCancer Letters xx (2006) 1–7www.elsevier.com/locate/canlet
Fig. 1. Example of RFLP analysis of XPD exon 6 genotypes. AA
genotype—fragment of 288 bp; CC genotype—fragments of 82 bp
plus 206 bp. (M—100 bp ladder).
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transcription factor TFIIH with ATPase-driven 5 0–3 0
helicase activity [6], being responsible for the separ-
ation of the DNA strands during DNA repair [7].
Several polymorphisms in the XPD gene have been
identified [8]. Recent studies have shown that two
common polymorphisms in the XPD gene may be
associated with differential DNA repair capacity
[9–12]. The Asp312Asn XPD polymorphism is charac-
terized by a G–A change, being responsible for aspartic
acid (Asp) to asparagine (Asn) amino acid substitution
in the coding region of the XPD gene [8]. The other
common polymorphism is located in codon 751 and
gives rise to a A/C change, resulting in lysine (Lys) to
glutamine (Gln) amino acid substitution in coding
region of XPD gene [8], being designed as Lys751Gln
XPD polymorphism. The frequencies of these poly-
morphisms are present in 29–46% of Caucasian
population [5,8,9]. Another frequent polymorphism in
XPD gene is located in exon 6, codon 156, with a nearly
frequency of 25% in health Caucasian population (8).
The C156A XPD polymorphism results in a C/A
change, being a silent alteration [8]. Given, the
importance of the XPD gene in multiple tasks such as
RNA transcription and NER pathway, the XPD
polymorphisms may operate as an important candidate
in genetic susceptibility factors in commonly occurring
forms of cancer.
In human ovarian cancer, it has been reported a
frequent loss of heterozygoty on chromosome 19q
[13,14]. The DNA repair gene XPD/ERCC2 is located
on 19q13.2–13.3. Dabholkar et al. [15] reported
abnormalities of mRNA expression of XPD that may
be characteristic of epithelial ovarian carcinoma.
The aim of this study is to evaluate the influence of the
C156A, Asp312Asn and Lys751Gln XPD polymorphisms
in the individual susceptibility to ovarian cancer.
2. Materials and methods
2.1. Patients
We evaluated the association between XPD exon 6, exon
10 and exon 23 polymorphisms and risk of ovarian cancer
using a case–control study. One hundred and twenty-six
patients with histologically confirmed epithelial ovarian
carcinoma and sequentially admitted at the Portuguese
Oncology Institute-Porto, in the Northern area of Portugal,
since 1999–2001, were included in this study. They were
evaluated according to the staging system of the International
Federation of Gynaecology and Obstetrics (FIGO). Infor-
mation on ovarian cancer patients was available from clinical
archive files. All cases were from Caucasian ethnicity and themean age of the patients was 54 years. The control group
consisted of 202 healthy women, with a median age of 54.3
years, who did not present a clinical history of cancer, and
were residents in the same geographic area of the cancer
group. Ethnicity information was available for all of control
subjects (100% Caucasian). Informed consent was obtained
from each patient and healthy individuals.2.2. Polymerase chain reaction/restriction fragment length
polymorphisms (PCR-RFLP) analysis
DNA was extracted from leukocytes of peripherical blood
by proteinase K/cloroform/isopropanol treatment [16].
Genotyping for C156A, Asp312Asn and Lys751Gln XPD
polymorphisms was carried out using previously described
PCR-RFLP methods (Hemminki et al., 2001, C156A
polymorphism; Matullo et al., 2001, Asp312Asn polymorph-
ism; Hemminki et al., 2001, Lys751Gln polymorphism)
[17,18]. PCR products were digested with specific restriction
endonuclease enzymes C156A polymorphism PCR product
was digested ith 10U Hinf I (Fermentasw) for more than 18 h
at 37 8C, followed by electrophoresis in 3% agarose gel. The
C allele was represented by 82 plus a 206 base pair (bp)
fragments and the A variant allele by a 288 bp fragment
(Fig. 1). Asp312Asn polymorphism PCR products were
digested with 10 U Taq I (Fermentasw) for more than 18 h
at 65 8C. The G allele was cut into two fragments (166 and
22 bp), while the A allele was represented by a 188 bp
fragment (Fig. 2). Lys751Gln polymorphism PCR products
were digested with 10U Pst I (Fermentasw) for more than 16 h
at 37 8C. A and C allele were visualized as fragments of 161
and 41 bp plus 120 bp, respectively, after separated by
electrophoresis in a 3% agarose gel (Fig. 3).
Fig. 2. Example of RFLP analysis of XPD exon 10 genotypes. AA
(Asn312Asn) genotype—fragment of 188 bp; GG (Asp312Asp)
genotype—fragments of 22 bp (not visualized) plus 166 bp.
(M—100 bp ladder).
Fig. 3. Example of RFLP analysis of XPD exon 23 genotypes. AA
(Lys751Lys) genotype—fragment of 161 bp; CC (Gln751Gln)
genotype—fragments of 41 bp (not visualized) plus 120 bp.
(M—100 bp ladder).
Table 1
Frequencies and odds ratio (OR) of C156A, Asp312Asn and
Lys751Gln XPD polymorphisms among ovarian cancer cases and
control individuals
Genotypes Controls n
(%)
Cases n
(%)
OR (95% CI) P-
value
Exon 6 (C156A)
CC/CA 147 (78.4) 97 (82.2) Reference 0.418
AA 40 (21.6) 21 (17.8) 0.79
(0.44–1.41)
Exon 10 (Asp312Asn)
Asp/Asp vs
Asp/Asn
184 (92.5) 95 (83.3) Reference 0.013
Asn/Asn 15 (7.5) 19 (16.7) 2.45
(1.19–5.04)
Exon 23 (Lys751Gln)
Lys/Lys vs
Lys/Gln
190 (94.1) 104 (82.5) Reference 0.001
Gln/Gln 12 (5.9) 22 (17.5) 3.35
(1.59–7.04)
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Chi-square (c2-test) analysis was used to compare
categorical variables. The odds ratio (OR) and its 95%
confidence interval (CI) were calculated to measure the
association between XPD allelic variants and ovarian cancer.Logistic regression analysis was used to calculate the adjusted
OR and 95% CI for the influence of XPD genotypes in the risk
of ovarian cancer, adjusted for age. A stratification of both
patient and control groups was made according to mean age of
these groups (women older than 54 years vs women younger
than 54 years).
We calculated the attributable proportion (AP) [19], as the
fraction of disease attributable to the risk factor.
Whenever appropriate, the observed number of each
genotype was compared with that expected for a population
in the Hardy–Weinberg Equilibrium by using a goodness of fit
c2-test.3. Results
The distribution of C156A, Asp312Asn and
Lys751Gln XPD polymorphisms among ovarian cancer
cases and controls is shown in Table 1. The frequency
of the C156A XPD genotypes was 0.20, 0.58 and 0.22 to
CC, CA and AA, respectively, in control group and 0.30,
0.52, 0.18 in cases. No significant differences were
found in the distribution of C156A genotypes in ovarian
cancer cases and controls. The Asp312Asp genotype
frequencies are 0.55 and 0.54 in control group and in
cases group, respectively. We found that patients with
ovarian cancer had a higher frequency of Asn312Asn
genotype than the control group (16.7 vs 7.5%). When
we considered Asp312Asp plus Asp312Asn genotypes
as a reference group, we observed that women carriers
Asn312Asn genotype were at increased risk of
developing ovarian cancer (ORZ2.45 95%CI 1.19–
5.04; PZ0.013). Logistic regression analysis con-
firmed this association of Asn312Asn genotype with a
statistically significant increase of ovarian cancer risk
Table 2
Multivariate analysis for the presence of risk genotypes and
susceptibility to ovarian cancer and the onset of ovarian cancer
under the age of 54 years
Increased
risk for
Genotypes OR 95% CI P-value
Cancer
Asn/Asn (exon 10) 2.46 1.20–5.06 0.015
Gln/Gln (exon 23) 3.40 1.61–7.15 0.001
Cancer onset under age of 54 years
Asn/Asn (exon 10) 3.63 1.34–9.83 0.011
Gln/Gln (exon 23) 5.15 1.89–14.05 0.001
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genotype carriers have a significant increase of ovarian
cancer risk under the age of 54 years, being this
association confirmed by logistic regression analysis
(Table 2; ORZ3.63; 95% CI 1.34–9.83; PZ0.011).
The frequency of the Lys751Lys genotype in our control
group was 0.47 and 0.44 in cases group. We found that
Gln751Gln genotype was more frequent in the ovarian
cancer group (17.5%) than in the control group (5.9%)
(Table 1). We demonstrate that carriers of this genotype
have an increased risk of developing ovarian cancer
(ORZ3.35 95% CI 1.59–7.04; PZ0.001). This
association was confirmed by logistic regression
analysis, performing an adjustment of OR for median
age (Table 2). Furthermore, this association was
stronger for the onset of ovarian cancer under the age
of 54 years confirmed by logistic regression analysis
(Table 2; ORZ5.15 95% CI 1.89–14.05; PZ0.001).
For the entire case group, the proportion of ovarian
cancer cases attributable to the Asn312Asn genotype
and Gln751Gln genotype was 9.9 and 12.4%, respect-
ively. When considering the age of onset younger of
ovarian cancer of 54 years the proportion of ovarian
cancer cases attributable to the Asn312Asn genotype
and Gln751Gln genotype was 14.5 and 21.0%, respect-
ively.
Subjects were cross-classified by Asn312Asn and
Gln751Gln genotypes in Table 3. We found that theTable 3
Combination between the Asn312Asn and Gln751Gln genotypes in controls
Genotypes Controls C
All cases
Asn/Asn and Gln/Gln 8 (4.1) 1
Others* 185 (95.9) 9
Onset under age of 54 years
Asn/Asn and Gln/Gln 4 (3.8) 1
Others* 102 (96.2) 4
*No Asn/Asn and Gln/Gln genotypes; **PZ0.016; ORZ3.10 95% CI 1.24–7
ORZ5.24 95% CI 1.56–17.55, using logistic regression analysis adjustingcarriers of both of these genotypes have a threefold
increase in ovarian cancer risk (ORZ3.10; 95% CI
1.24–7.75; PZ0.016). The risk was further increased in
the age of onset of 54 years (ORZ5.24 95% CI 1.56–
17.55; PZ0.007).
The observed genotype distributions for C156A,
Asp312Asn and Lys751Gln XPD are in agreement with
Hardy–Weinberg Equilibrium.
The clinicopathological features in ovarian cancer
patients according to XPD genotypes are shown in
Table 4. We did not find significant statistical differ-
ences between groups of patients with A156A homo-
zygote variant and others genotypes, regarding age at
diagnosis, clinical stage and histologicaltype and grade.
We observed a higher frequency of Asn312Asn and
Gln751Gln genotypes in ovarian cancer patients
presenting I/II stage than patients with III/IV stage,
being these differences statistically significant (PZ
0.005; PZ0.014, respectively). Another statistical
significant difference was observed when we compared
the group of patients with I histological grade and II/III
presenting Gln751Gln homozygote variant (PZ0.018).4. Discussion
In this study, we examined the association between
C156A, Asp312Asn and Lys751Gln XPD polymorph-
isms and ovarian cancer susceptibility in a Portuguese
population. This is the first study assessing the
relationship between XPD polymorphisms and ovarian
cancer risk.
Ovarian cancer is an aggressive disease with an
increasing mortality. It is elementary to elucidate the
aetiology of this form of cancer to be able to an early
detection and to achieve a possible prevention.
The XPD protein is involved in different cellular
processes. It is integrated in TFIIH complex, which is
involved in multiple tasks, as transcription and
phosphorylation of numerous substrates [20,21]. Also
it is essential to NER pathway, where it has a helicaseand ovarian cancer cases
ases OR (95% CI) P-value
3 (11.6) 3.04 (1.22–7.57) 0.013**
9 (88.4)
0 (16.9) 5.20 (1.55–17.43) 0.004***
9 (83.1)
.75, using logistic regression analysis adjusting for age; ***PZ0.007;
for age.
Table 4
Relation between C156A, Asp312Asn and Lys751Gln XPD genotypes and clinicopathological parameters in ovarian cancer
Parameter C156A genotypes P-value Asp312Asn genotypes P-value Lys751Gln genotypes P-value
Homozy-
gote variant
Others Homozy-
gote variant
Others Homozy-
gote variant
Others
Age
(years)*
51.3G16.1 54.6G13.6 0.426** 52.8G13.9 54.3G14.2 0.574** 51.0G14.5 54.6G14.0 0.307**
FIGO stage
I/II 6 (16.2) 31 (83.8) 0.846*** 11 (30.6) 25 (69.4) 0.005*** 13 (29.5) 31 (70.5) 0.014***
III/IV 11 (17.7) 51 (82.3) 5 (8.5) 54 (91.5) 7 (10.9) 57 (89.1)
Histological grade
I 2 (9.5) 19 (90.5) 0.304*** 6 (31.6) 13 (68.4) 0.018*** 6 (26.1) 17 (73.9) 0.214***
II/III 11 (19.3) 46 (80.7) 5 (9.1) 50 (90.9) 9 (14.5) 53 (85.5)
Histological type
Serous 9 (45.0) 49 (59.0) 0.256*** 10 (17.9) 46 (82.1) 0.837*** 11 (17.7) 51 (82.3) 0.722***
Others 11 (55.0) 34 (41.0) 7 (16.3) 36 (83.7) 10 (20.4) 39 (79.6)
*MeanGSD; **Mann–Whitney test; ***c2 test.
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activity of these processes, giving rise to repair and
transcription defects, abnormal responses to apoptosis
and, probably, hormonal dysfunctions.
In the present study, the variant allelic frequencies of
C156A, Asp312Gln and Lys751Gln XPD polymorphism
in control group are in agreement with previous
findings in other populations [5,9].
We did not observe any association between C156A
XPD polymorphism and genetic susceptibility to ovarian
cancer risk. We found that women that are carrier of the
Asn312Asn genotype have a near threefold risk of ovarian
cancer in comparison with women carriers Asp312Asp or
Asp312Asn combined. This suggests that the Asn312
allele may be a risk factor to ovarian cancer.
Furthermore, when we look to subgroups of cases
and control according to the mean onset age of disease,
we found that the risk of developing ovarian cancer is
almost a fourfold increase in women younger than 54
years that presented the Asn312Asn genotype. These
results are consistent with reports that suggest a lower
DNA repair capacity associated to Asn312Asn genotype
[9,10]. The XPD exon 10 polymorphism is character-
ized by a G/A nucleotide substitution, causing an
Asp/Asn amino acid change at codon 312 of XPD
gene [8]. The biological function of this amino acid
substitution has not yet been elucidated.
However, the fact that this residue has been highly
conserved through evolution [8,22] and give rise to an
amino acid substitution, suggests a strong effect in the
enzymatic activity of XPD protein. We also reported
that women with Gln751Gln XPD genotype have a 3.4-
fold-risk increased of ovarian cancer. The fact that this
genotype has been associated with a lower DNA repair
capacity [9,10] comes in agreement with our results.This association is even more noteworthy according to
age onset of cancer in women younger than 54 years.
The Gln751Gln XPD polymorphism results from a
A/C variation in codon 751 giving rise to the amino
acid substitution Lys to Gln [8], which is a change from
a basic to a polar amino acid. This completely changes
the electronic configuration of the amino acid, and is a
major change, located in the important domain of
interaction between XPD protein and its helicase
activator, inside the TFIIH complex [21]. In theory,
the consequence should be the most important in terms
of XPD activity. Furthermore, the Asp312Asn and
Lys751Gln XPD polymorphisms have been linked to
susceptibility to other cancers, namely in head and neck
[23], bladder [24], lung [25–28], melanoma [29,30],
oesophageal [31], breast [32,33] and prostate [34]. We
reported a stronger association of the Asp312Asn and
Lys751Gln XPD polymorphisms with ovarian cancer
risk in women in early-stage of disease. This could
suggest the involvement of this gene merely in
initiation rather than in progression of the disease.
The association between Asn312Asn and Gln751Gln
XPD polymorphisms and ovarian cancer is biologically
plausible, because the XPD protein functions as a 5 0–3 0
helicase in the NER mechanism, which is responsible
for the repair of many DNA lesions [2] and plays a role
in activating apoptosis through interaction between p53
and TFIIH to remove damaged cells [35,36].
Furthermore, the Gln751Gln XPD polymorphism is
located in an important domain responsible for the
interaction between XPD protein and p44 protein, its
helicase activator, inside the TFIIH complex [21].
There is strong evidence suggesting estrogens as the
relevant hormone in hormonal etiology of ovarian
cancer [37–39]. Some experimental evidences have
S. Costa et al. / Cancer Letters xx (2006) 1–76
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species that react with DNA to form depurinating
adducts and thereby initiate cancer, namely ovarian
cancer [40,41]. In this way, XPD protein, as a member
of NER, could represent an important molecule in
carcinogenesis of ovarian cancer. Another support of
the importance of XPD in ovarian carcinogenesis is it
localization in chromosome 19q13.3 region, region
with frequent loss of heterozygosity in epithelial
ovarian carcinoma [13,14]. This region encodes several
others genes involved in DNA repair, for example,
ERCC1 and XRCC1, and linkage disequilibrium
between these polymorphisms and other DNA repair
genes may occur leading to a possible explanation to a
low DNA repair capacity in ovarian cancer patients.
Our study is the first to associate XPD polymorphisms
with ovarian cancer susceptibility. Our results suggest
that the Asn312Asn and Gln751Gln XPD polymorphisms
may be a genetic risk factor to ovarian cancer and
particularly associated with an earlier onset of ovarian
cancer. However, this study has some limitation, being
the most important the sample size and the lack of a
replicating study. A recent report suggests that studies
regarding the association between genetic variants and
cancer must have in account not only the statistical
significance (P-value) but also the false positive report
probability (FPRP) [42]. Future studies in other popu-
lations using a large sample of cases and controls and the
FPRP criterion will be helpful to confirm our results.
Genetic polymorphisms in DNA repair genes or other
genes, contributing to low to-moderate cancer risk, may
be important for a better understanding of the molecular
epidemiology of ovarian cancer [19,43–47]. As well,
this definition could help to outline chemoprevention
strategies. Furthermore, since XPD proteins are essen-
tial to the NER pathway responsible for the removal of
DNA adducts produced by platinum agents such as
cisplatin, which is commonly used in chemotherapy of
ovarian cancer [48], it would be also important to study
the influence of these polymorphisms in the response to
chemotherapy and overall survival.
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